BioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $118.00.

A number of equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $113.00 price objective on shares of BioNTech in a report on Monday. JPMorgan Chase & Co. upgraded shares of BioNTech from an “underweight” rating to a “neutral” rating and increased their price target for the company from $91.00 to $125.00 in a research report on Monday. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. TD Cowen reduced their target price on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Finally, Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research note on Wednesday, August 7th.

BioNTech Trading Up 1.0 %

Shares of BNTX opened at $124.71 on Friday. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a market capitalization of $29.65 billion, a P/E ratio of 249.42 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The firm’s 50 day simple moving average is $88.13 and its 200 day simple moving average is $89.90.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business’s revenue was down 23.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.86) earnings per share. Sell-side analysts forecast that BioNTech will post -2.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Harding Loevner LP bought a new stake in shares of BioNTech in the 4th quarter worth approximately $410,984,000. Candriam S.C.A. raised its stake in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares in the last quarter. Primecap Management Co. CA grew its stake in shares of BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after acquiring an additional 60,270 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.